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The aim of this study, using a Fleming single-stage design, was to explore the efﬁcacy and safety of Taxotere
1 100 mg m
72
docetaxel and FEC 75 cyclophosphamide 500 mg m
72, ﬂuorouracil 500 mg m
72 and epirubicin 75 mg m
72, in alternating
and sequential schedules for the ﬁrst-line treatment of metastatic breast cancer. One hundred and thirty-six women were
randomly allocated, to one of three treatment regimens: DTX 100 plus FEC 75, alternated for eight courses (ALT); four
courses of DTX 100 followed by four courses of FEC 75 (SEQ T); or four courses of FEC 75 followed by four courses of
DTX 100 (SEQ F). One hundred and thirty-one women were evaluable for tumour response. Although the treatment
outcome was equivalent in the two sequential arms and the alternating regimen (P=0.110, not signiﬁcant), the response rate
was less encouraging in the SEQ F arm (52.3%) than in the other two arms (71.1% for ALT and 70.5% for SEQ T), in which
docetaxel was administered ﬁrst. Time to progression was similar in the ALT, SEQ T and SEQ F arms (9.5, 9.3 and 10.4
months respectively). Grade 3–4 neutropenia was observed in nearly all patients; febrile neutropenia occurred in 9% (ALT),
16% (SEQ T) and 2% (SEQ F) of patients. Few patients (49%) developed grade 3–4 non-haematological toxicities. Relative
dose intensity was 97–99% for all regimens. All treatment regimens were active and well tolerated.
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Despite recent advances in cancer therapies, metastatic breast
cancer (MBC) still carries a poor prognosis. About 40% of patients
with breast cancer will develop metastatic disease, either at diagno-
sis (about 7% of patients) (Wingo et al, 1995) or, more commonly,
at the time of recurrence. Furthermore, median survival remains at
about 2–3.5 years after documentation of metastasis (Clark et al,
1987; Henderson, 1991; Campora et al, 1999).
The main aim of chemotherapy in MBC is palliative. However,
chemotherapy can also improve survival and may enhance quality
of life (Fossati et al, 1998). The anthracyclines have long been
considered to be the most active agents in MBC, with reported
response rates of about 50% for monotherapy (Findlay and Walk-
er-Dilks, 1998; Ormrod et al, 1999). Of the newer agents now
available, docetaxel (Taxotere), a semi-synthetic taxoid, has shown
the most promising activity of all the compounds used so far in
MBC, even in anthracycline-resistant tumours (Van Oosterom,
1995; Bonneterre et al, 1999; Chan et al, 1999; Nabholtz et al,
1999; Sjo ¨stro ¨m et al, 1999). Several phase III trials have now estab-
lished docetaxel as the most active single agent in MBC (Chan et
al, 1999; Nabholtz et al, 1999).
The failure of chemotherapy to produce a cure in MBC is
thought to be linked to the development of drug resistance by the
tumour cells. One strategy, aimed at overcoming this phenomenon,
involves the use of non-cross-resistant chemotherapy regimens.
Cyclophosphamide plus methotrexate and ﬂuorouracil (CMF) was
one of the ﬁrst combinations to be investigated in breast cancer.
Response rates of between 50 and 60% have been reported (Bona-
donna et al, 1995). The addition of doxorubicin to combination
regimens in MBC is associated with improved response rates (to
between 60 and 80%) in advanced breast cancer (A’Hern et al,
1993; Fossati et al, 1998). However, no survival beneﬁt has been
demonstrated (Fossati et al, 1998). Commonly used ﬁrst-line
anthracycline-containing regimens involve the addition of either
doxorubicin or epirubicin to ﬂuorouracil and cyclophosphamide
(FAC or FEC, respectively) (French Epirubicin Study Group,
1988; Italian Multicentre Breast Study with Epirubicin, 1988).
However, improvements in tumour response rates achieved by
combination therapies are frequently hampered by an increase in
toxicity (Fossati et al, 1998). It has been suggested that toxicity
can be reduced if different components of chemotherapeutic regi-
mens are administered either alternately (Goldie et al, 1982) or
sequentially (Day, 1986). To date, few studies have been conducted
using alternating or sequential regimens or both in MBC.
The aim of the present study was to evaluate the effect of adding
docetaxel to the FEC regimen in the ﬁrst-line treatment of MBC,
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www.bjcancer.comand to determine whether the use of either an alternating or a
sequential schedule could alter the efﬁcacy or cumulative toxicity
of the combination.
MATERIALS AND METHODS
Patient selection
Between September 1996 and March 1998, 136 women aged 418
years and 575 years, with histologically or cytologically conﬁrmed
MBC, were recruited into the study. Patients with measurable MBC
(bidimensionally measurable lesions: nodes or skin and subcuta-
neous metastases 510610 mm, lung metastases 510610 mm
on chest X-ray or 20610 mm on CT scan, and at other sites
520610 mm on CT scan) were eligible for the study. Prior
chemotherapy, either in the neoadjuvant or adjuvant setting, was
permitted, provided that relapse had occurred more than 12
months after completion of the chemotherapy. Prior anthracy-
cline-containing chemotherapy was permitted if the cumulative
dose of doxorubicin was 4300 mg m
72 (or 4450 mg m
72 epir-
ubicin, or 475 mg m
72 mitoxantrone). Prior hormone therapy
was also permitted, provided it was discontinued at entry into
the study. Prior radiotherapy was permitted for palliative purposes,
except if the irradiated site was involved in disease evaluation.
Radiotherapy was required to be completed at least 4 weeks before
study entry and previously irradiated lesions were not evaluable,
except in the case of disease progression.
All patients were required to have a WHO performance status of
42; adequate bone marrow function (granulocyte count
52610
9 l
71, platelet count 5100610
9 l
71); adequate renal func-
tion (serum creatinine level 4135 mmol l
71, or creatinine
clearance 460 ml min
71); adequate liver function (bilirubin level
41.25 times normal level, ASAT and ALAT levels 42 times normal
level, alkaline phosphatases 52.5 times normal level). In addition, all
patients were required to have a resting left ventricular ejection frac-
tion of 550% of normal values, or greater than the lower limit of
normal (on echocardiographic or radionucleotide scan).
Exclusion criteria included: prior chemotherapy with taxoids
(paclitaxel, docetaxel), or contra-indications to corticosteroid
therapy; local relapse after conservative surgery alone, or
advanced inoperable localised breast cancer; and CNS metastases.
Bone metastases, pleural effusion or ascites, or carcinomatous
lymphangitis were not permitted as the only evidence of meta-
static disease. Patients who had received prior chemotherapy
for metastatic disease were not eligible. Additional exclusion
criteria were: unstable heart disease requiring treatment; uncon-
trolled infectious disease; psychiatric or neurological disorders;
a history of neoplasm other than breast cancer, with the excep-
tion of non-melanoma skin cancer or curatively treated in-situ
cervical cancer.
The protocol was approved by an ethical committee and all
patients provided written, informed consent before study entry.
Randomisation and study treatments
Registration forms were faxed to Aventis Pharma (Montrouge,
France) and the treatment schedule was allocated according to a
randomisation list created electronically. Patient groups were stra-
tiﬁed by centre and allocated in equal proportion to the three
treatments.
Patients who fulﬁlled the eligibility criteria were randomised to
receive either alternating therapy with docetaxel (DTX) and FEC
for eight cycles (ALT), or four cycles of DTX followed by four cycles
of FEC (SEQ T), or four cycles of FEC followed by four cycles of
DTX (SEQ F). Each regimen was repeated every 21 days. DTX
100 mg m
72 was administered by 1-h infusion; the premedication
schedule consisted of oral prednisolone 50 mg given 13, 7 and
1 h before DTX, 50 mg on the evening of the infusion, and
50 mg twice a day for 3 days after infusion (for a total of 10 doses).
The calculated dose of DTX was diluted in 5% dextrose or normal
saline to produce a maximal concentration of 1 mg ml
71. Vital
signs were monitored before and during DTX administration.
The FEC regimen was administered on day 1 of each treatment
cycle and consisted of an intravenous (i.v.) infusion of cyclophos-
phamide 500 mg m
72, an i.v. bolus of ﬂuorouracil 500 mg m
72,
and an i.v. infusion of epirubicin 75 mg m
72. Epirubicin was
reconstituted with 0.9% normal saline or sterile water for injection
to produce a maximal ﬁnal concentration of 2 mg ml
71. Epirubi-
cin was given as a 30–60 min infusion. Fluorouracil and
cyclophosphamide were diluted in 5% dextrose or normal saline.
Vital signs were monitored before and during FEC administration.
Toxicity and dose modiﬁcations
Toxicity was evaluated and graded according to the National
Cancer Institute Common Toxicity Criteria.
The doses of both DTX and epirubicin were adjusted in the
event of febrile neutropenia, or when a delay of 47 days was
necessary for the absolute neutrophil count to recover to
50.5610
9 l
71. A platelet count of 5100610
9 l
71 was also neces-
sary for treatment to be recommenced. In these circumstances,
DTX was reduced to 75 mg m
72, and epirubicin to 50 mg m
72.
Systematic prophylactic administration of granulocyte colony-
stimulating factor (G-CSF) was not permitted. Treatment of
neutropenic complications was left to the discretion of the clini-
cian.
In the event of nausea and vomiting of grade 53, and/or muco-
sitis of grade 3/4, the dose of DTX was reduced to 75 mg m
72,
then to 55 mg m
72, as necessary, and the epirubicin dose was
reduced to 50 mg m
72. If other grade 3 toxicities were reported
(excluding alopecia and anaemia) treatment was delayed for a
maximum of 2 weeks, until resolution to grade 1 or lower. Treat-
ment was then restarted with the dose reductions described. If
treatment was required to be delayed for longer than 2 weeks,
the patient was withdrawn from the study.
Patient and treatment evaluation
A complete medical history and physical examination with tumour
measurement were performed in all patients and before each cycle
of treatment. Complete blood cell counts with platelet counts were
performed weekly, and biochemical parameters were assessed every
3 weeks.
The type of imaging procedures used depended on the tumour
location and imaging was repeated after the second, fourth, sixth,
and eighth treatment cycles. Each objective response was conﬁrmed
at least 4 weeks after initial detection and was reviewed by a panel
of independent radiologists.
The duration of partial response was calculated from the
start of treatment until the ﬁrst documentation of progressive
disease, while the duration of complete response (CR) was
from the ﬁrst time the CR was documented. Time to ﬁrst
response and time to progression were calculated from the
ﬁrst administration of the drugs to the ﬁrst occurrence of
response and ﬁrst progression, respectively. Survival was calcu-
lated from the date of the ﬁrst administration of the study
drugs to death.
Study design
The study was designed using Fleming’s one-sample multiple test-
ing procedure for phase II clinical trials (Fleming, 1982). This
procedure allows for the pre-speciﬁcation of a minimum response
rate to treatment (i.e. one below which the treatment would be
considered insufﬁciently active), as well as the pre-speciﬁcation of
a response rate above which the treatment would be considered
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provide for a statistical comparison between treatment arms:
rather, it is a vehicle that allows investigators to examine efﬁcacy
in a number of different treatment arms, and, if necessary, to then
curtail one or more of these arms prematurely, if patients do not
reach a pre-speciﬁed level of response. Thus, the current study
was a prospective, open, single-centre, phase II study to assess
the efﬁcacy and safety of docetaxel plus FEC, in three administra-
tion schedules, in patients with MBC. The primary endpoint was
the efﬁcacy of treatment, deﬁned as overall response rate, duration
of response, time to progression and overall survival. The second-
ary objective was to compare the safety proﬁle of the three
treatment regimens.
Statistical analysis and calculation of the sample size
The required number of patients was determined according to a
single stage Fleming design (Fleming, 1982). The statistical
hypotheses were the same for the three treatment arms. That
is to say, the design parameters that were used considered a
treatment to be insufﬁciently active if the response rate was
445%, and sufﬁciently active if the response rate was 560%.
With an error rate of 10% and a power of 73%, 40 evaluable
patients needed to be included in each of the three arms. Any
statistical analysis was performed on the intention-to-treat
group.
RESULTS
Patient characteristics
The patient and tumour characteristics were well balanced between
the three treatment groups, except that the combined incidence of
liver and bone involvement was lower in the SEQ F arm than the
other two arms (Table 1). Among the 136 patients who entered the
study, 133 were treated and 131 were evaluable for efﬁcacy. The
reasons for non-treatment were: withdrawal of consent (n=1), suicide
(n=1), and biological abnormalities (n=1). Five patients were not
evaluable for efﬁcacy because they received fewer than two cycles of
chemotherapy (n=4), and/or their tumours were not assessed.
About half of the patients had already received previous anthra-
cycline-based chemotherapy (adjuvant and/or neoadjuvant).
Overall median time interval from diagnosis to the ﬁrst infusion
was 39 months (range 0–380 months).
Treatment exposure
The majority of patients completed the eight courses of planned
therapy: 87.6% in the ALT arm, 81.8% in the SEQ T arm, and
75.0% in the SEQ F arm (Table 2). Two per cent of patients in
each arm stopped treatment due to toxicity. Tumour progression
was responsible for cessation of therapy in 11.1% in the ALT
arm, 13.6% in the SEQ T arm, and 15.9% in the SEQ F arm.
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Table 1 Patient characteristics
ALT SEQ T SEQ F
Patients (n=133) 45 44 44
Median age (years) (range) 53 (34–74) 52 (32–74) 58 (31–73)
Menopausal women (% patients) 85 79 87
WHO Performance Status=0 or 1 (% patients) 100 95.5 90.9
Metastatic sites (% patients)
Lymph nodes 44.4 40.9 47.7
Lung 40 40.9 52.3
Liver 44.4 59.1 47.7
Bone 46.7 56.8 29.5
Breast 6.7 25 22.7
Skin 13.3 9.1 15.9
Other sites 11.1 13.6 12
53 organs involved (% patients) 28.9 40.9 29.5
Median time interval from diagnosis to the ﬁrst infusion 41 (0–380) 37 (0–176) 33 (0–172)
(months) (range)
Histological subtype (% patients)
IDC 64.4 59.1 72.7
ILC 4.4 6.8 6.8
ISC 0 2.2 0
IDC+ISC 0 4.5 4.5
ILC+ISC 0 0 2.3
Undetermined 20.0 22.7 11.4
Missing information 11.1 4.5 2.3
Tumour stage (% patients)
0 0 4.5 0
I 11.1 9.1 6.8
IIA+IIB 40.0+20.0 27.3+27.3 43.1+17.8
IIIA+IIIB 6.6+44 11.4+2.3 4.5+0
IV 13.3 15.9 22.7
Undetermined 2.2 2.3 2.3
Prior treatment (% patients)
Surgery 95.5 79.5 86.3
Radiotherapy 84.4 77.3 68.2
Neo- and/or adjuvant chemotherapy 62.2 52.3 52.3
Anthracycline-based chemotherapy 62.2 50.0 50.0
IDC=invasive duct carcinoma; ILC=invasive lobular carcinoma; ISC=in situ carcinoma.
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initially planned time and dose. Consequently, the relative dose
intensity (RDI) was excellent for both drugs: the RDI for docetaxel
was 99% (95% CI: 66–105%) in the ALT arm, 97% (95% CI: 75–
103%) in the SEQ T arm, and 97% (95% CI: 76–103%) in the
SEQ F arm; the RDI for epirubicin was 97% (95% CI: 53–
108%) in the ALT arm, 95% (95% CI: 64–102%) in the SEQ T
arm, and 96% (95% CI: 71–103%) in the SEQ F arm.
Efﬁcacy
The overall response rate (complete plus partial responses) was
high in the three groups, but higher in the ALT (71.1%) and
SEQ T (70.5%) arms than in the SEQ F arm (52.3%) (Table 3).
Complete responses were observed in 8.9% of patients in the
ALT arm, 2.3% in SEQ T and 11.4% in the SEQ F arm. There were
more cases of stable disease in the SEQ F arm. Median duration of
response and median time to progression were similar in the three
groups (Table 3).
The 2-year survival was similar in the three treatment groups,
with a 58% survival rate in the ALT arm, 52% for the SEQ T
arm, and 51% for the SEQ F arm. Note that the Fleming study
design is not intended to differentiate statistically between the efﬁ-
cacies and the survival rates of these three arms, hence the P-values
(Table 3) are non-signiﬁcant.
Median duration of survival was also similar in the three groups.
One patient died from progressive disease during the study (SEQ T
arm). A further 10 patients died from disease progression after the
end of therapy (three patients in the ALT arm, three in the SEQ T
arm and four in the SEQ F arm).
The median follow-up period for the whole study population
was 19.4 months (range 0.4–34.2 months).
Safety
There were no deaths due to toxicity during the study. There was
no difference in terms of toxicity between the three arms (Tables
4 and 5). However, 9% of patients in the ALT arm, 16% in the
SEQ T arm and 2% in the SEQ F arm experienced febrile neutro-
penia. There was only one documented infection with febrile
neutropenia during one FEC course in the ALT arm. Four
patients received G-CSF for grade IV neutropenia. However, these
four patients did not receive prophylactic G-CSF in subsequent
cycles.
Non-haematological toxicity, grades 3 and 4, was infrequent in
all treatment groups (49% of patients). Grade 3 or 4 ﬂuid reten-
tion or neurosensory disorders were not observed in any of the
treatment arms.
DISCUSSION
The present study is the ﬁrst to evaluate the efﬁcacy and tolerability
of one of the recently available taxoids in alternating and sequential
schedules for the treatment of MBC.
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Table 2 Reasons for stopping treatment
ALT SEQ T SEQ F
(%) (%) (%)
Administration of the eight planned cycles 86.7 81.8 75.0
Toxicity
a 2.2 2.3 2.3
Tumour progression 11.1 13.6 15.9
Consent withdrawal 0 0 4.5
Protocol deviation 0 0 2.3
Death 0 2.3 0
aCardiac toxicity, two patients; lymphoedema, one patient.
Table 3 Efﬁcacy results
ALT SEQ T SEQ F
n=45 n=44 n=44
Objective response (%) (95% CI) 71.1 (57.8–84.3) 70.5 (57.0–84.0) 52.3 (37.5–67)
CR (%) 8.9 2.3 11.4
PR (%) 62.2 68.2 40.9
P=0.110
a
Stable disease (%) 22.2 20.5 36.4
Progressive disease (%) 6.7 6.8 9.1
Non evaluable (%) 0 2.3 2.3
Median time to ﬁrst response (days) (95% CI) 59 (42–78) 79 (75–84) 86 (71–124)
Number of patients with progression after the 1st sequence/with Not applicable 9/2 9/2
response after the 2nd sequence
Median duration of response (months) (95% CI) 9.5 (8.8–11.8) 9.3 (8.3–11.6) 9.8 (8.4–10.4)
Median time to progression (months) (95% CI) 9.5 (8.8–11.8) 9.3 (7.8–11.6) 10.4 (8.4–13.0)
Objective response rate in patients with previous anthracycline 75 68 43
exposure (%)
Median survival (months) (95% CI) 22.8 (22.8–422.8) 24.8 (16–32.5) 29.0 (15.6–429)
2-year survival (%) 58 52 51
P=0.750
a
aNo statistical difference between the three regimens concerning the objective response and the survival rates.
Table 4 Incidence of haematological toxicity
ALT (%) SEQ T (%) SEQ F (%)
All Gr 3–4 All Gr 3–4 All Gr 3–4
Neutropenia 100 96 100 98 98 93
Thrombocytopenia 80 4 77 0 66 5
Anaemia 93 2 86 0 95 7
Febrile neutropenia 9* 16* 2*
Gr 3–4=Grade 3–4 toxicity (NCI criteria). *Neutropenia grade 4 with concomitant
fever 5grade 2 requiring IV antibiotics and/or hospitalisation.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 692–697Several phase III trials have established docetaxel as the most
active single agent in MBC. A recent large randomised trial demon-
strated improved survival with docetaxel compared with
combination therapy with mitomycin C plus vinblastine in patients
with MBC who had progressed despite prior anthracycline-contain-
ing chemotherapy (Nabholtz et al, 1999). In another multicentre,
randomised phase III trial a higher response rate was observed with
docetaxel (47.8%) compared with doxorubicin (33.3%) in patients
with MBC who had received prior alkylating agent-containing
chemotherapy (Chan et al, 1999).
In an effort to overcome the possible development of drug resis-
tance by the tumour cells, non-cross-resistant combination
regimens have been used. Doxorubicin or epirubicin have been
added to ﬂuorouracil and cyclophosphamide (FAC or FEC, respec-
tively). These regimens appear to have equivalent efﬁcacy in MBC,
but several studies have shown that the FEC regimen is more
convenient to administer than FAC, and is also associated with
lower toxicity than FAC (French Epirubicin Study Group, 1988;
Italian Multicentre Breast Study with Epirubicin, 1988). These
studies reported response rates with the FEC regimen of 43 to
64%. Furthermore, increasing the dose of epirubicin from 50 to
75 mg m
72 appears to improve the response rates in patients with
advanced breast cancer who are treated with the FEC regimen, with
no signiﬁcant effect on tolerability (French Epirubicin Study
Group, 1991; Ormrod et al, 1999).
Docetaxel has been associated with the development of myelo-
toxicity (Fumoleau, 1997) and epirubicin is also known to be
haematotoxic (Ormrod et al, 1999). Therefore, the combination
of these agents may be expected to produce additive haematotoxic
effects. Furthermore, epirubicin produces a cumulative cardiac
toxicity, especially at cumulative doses above 900 mg m
72 (Ryberg
et al, 1998; Gennari et al, 1999). It has been suggested that toxicity
can be reduced if different components of combination regimens
are administered either alternately (Goldie et al, 1982) or sequen-
tially (Day, 1986). A number of studies have investigated the role
of alternating or sequential regimens in the treatment of MBC.
Most of these trials appear to indicate no clear advantage of
sequential over alternating regimens.
A randomised study comparing sequential to alternating doxo-
rubicin and CMF therapy in the adjuvant treatment of patients with
breast cancer and more than three positive axillary nodes has already
been published (Bonadonna et al, 1995). The sequential regimen was
shown to be signiﬁcantly superior to the alternating one, in terms of
both relapse rates (42% vs 28%, P=0.002) and overall survival (58%
vs 44%, P=0.002). These results inﬂuenced the design of subsequent
clinical studies and may explain the large number of ongoing studies
that are evaluating sequential regimens in the adjuvant setting (Hudis
et al, 1999; Burris, 2000; Di Leo et al, 2000). It would appear, there-
fore, that further evaluation of sequential and alternating regimens is
necessary in MBC.
In the study reported here, which uses a Fleming one-stage
design (Fleming, 1982), with pre-speciﬁed parameters for criteria
the investigators would consider to be acceptable response rates,
it is interesting to note that no statistical difference in the treat-
ment outcome was demonstrated between the two sequential
arms and the alternating regimen (P=0.110, not signiﬁcant).
However, the response rate was less encouraging in the SEQ F
arm (52.3%) than in the other two arms (71.1% for ALT and
70.5% for SEQ T), in which docetaxel was administered ﬁrst,
despite a lower combined incidence of bone and liver metastases
among patients in the SEQ F arm. A poor response rate to
chemotherapy is generally observed in bone metastases and the efﬁ-
cacy of treatment is often difﬁcult to determine at this site
(Leonard et al, 1994). Furthermore, metastases in the liver are
known to be less chemosensitive than those at other sites.
None of the tested schedules was clearly superior in terms of
toxicity. The majority of cycles of the three regimens was adminis-
tered at the planned dose-intensity and was well tolerated, with no
cumulative toxicities being observed.
In conclusion, given that the aim of the present study was to
evaluate the effect of adding docetaxel to the FEC regimen for
the treatment of MBC, and to determine whether the use of either
an alternating or a sequential schedule could alter the efﬁcacy or
cumulative toxicity of this combination, our results indicate that
the addition of docetaxel to the FEC regimen is, indeed, active
in MBC, and that the ALT and SEQ T regimens warrant further
investigation.
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